{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:32:58Z","timestamp":1788024778692,"version":"build-2784847793"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002767","name":"Department of Science and Technology of Hunan Province","doi-asserted-by":"publisher","award":["AC20241010161788598dc3"],"award-info":[{"award-number":["AC20241010161788598dc3"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Ovarian cancer is a common malignant tumor of the female reproductive system, and traditional treatments are unsatisfactory due to its intraperitoneal spreading mechanism and its biologic characteristic of being prone to drug resistance. Pembrolizumab has demonstrated high objective remission and overall survival rates in a variety of solid tumors, and clinical trials are now available to explore its efficacy in the treatment of ovarian cancer. The objective of this systematic review and meta-analysis was to synthesize the findings of multiple clinical studies in order to evaluate the effectiveness and safety of the immunotherapeutic agent Pembrolizumab in patients diagnosed with advanced or recurrent ovarian cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search of literature published up to 19 November 2024 was conducted in the following databases: PubMed, Embase, Cochrane Library, Web of Science, Ovid_medline, Scopus, and ProQuest. The outcomes related to the administration of pembrolizumab in patients with advanced or recurrent ovarian cancer were extracted, including objective remission rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (AEs). A further meta-analysis was then performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This meta-analysis comprised 625 patients across nine studies. A total of 617 patients were involved in the efficacy assessment, while 592 patients were included in the safety assessment. The pooled analysis indicated an ORR of 24% (95% confidence interval [CI], 0.13\u20130.35), a DCR of 63% (95% CI, 0.49\u20130.77), a median progression-free survival (mPFS) of 4.82 months (95% CI, 3.29\u20136.35), and a median overall survival (mOS) of 13.54 months (95% CI, 10.35\u201316.73). Subgroup analysis indicated that the ORR in the PD-L1-positive group was 24% (95% CI, 0.12\u20130.36), while the ORR in the PD-L1-negative group was 18% (95% CI, 0.09\u20130.27). No statistically significant difference was observed between the two groups. The ORR was 26% (95% CI, 0.13\u20130.33) for patients administered a 200 mg dose every three weeks (q3w), while it was 12% (95% CI, 0.02\u20130.30) for those receiving a 10 mg\/kg dose every two weeks (q2w). The overall incidence of adverse reactions of any grade was 81% (95% CI, 0.71\u20130.91), whereas the incidence of grade 3 or higher adverse reactions was 32% (95% CI, 0.09\u20130.54).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This meta-analysis indicates that pembrolizumab treatment for patients with advanced or recurrent ovarian cancer exhibits significant efficacy and an acceptable safety profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/<\/jats:uri> identifier CRD42024620116.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1662455","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:51:59Z","timestamp":1759297919000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of pembrolizumab for the treatment of advanced or recurrent ovarian cancer: a meta-analysis based on single-arm studies"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaodong","family":"Mi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Tuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/biom14050585","article-title":"Oncogenic pathways and targeted therapies in ovarian cancer","volume":"14","author":"Lliberos","year":"2024","journal-title":"Biomolecules"},{"key":"B2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.224","article-title":"Can advanced-stage ovarian cancer be cured","volume":"13","author":"Narod","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.hoc.2024.08.013","article-title":"Surgical management of gynecologic cancers","volume":"39","author":"Clair","year":"2025","journal-title":"Hematol Oncol Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: A narrative review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.785153","article-title":"Current progress and future perspectives of immune checkpoint in cancer and infectious diseases","volume":"12","author":"Cai","year":"2021","journal-title":"Front Genet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7770","DOI":"10.1038\/s41598-025-91476-0","article-title":"Pharmacovigilance analysis of immune checkpoint inhibitor-related reproductive adverse effects based on the FDA adverse event reporting system","volume":"15","author":"K\u00f6yl\u00fc","year":"2025","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2146\/ajhp140768","article-title":"Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma","volume":"73","author":"Ivashko","year":"2016","journal-title":"Am J Health-syst Pharm: AJHP: Off J Am Soc Health-syst Pharm"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17162636","article-title":"IGSF11-mediated immune modulation: unlocking a novel pathway in emerging cancer immunotherapies","volume":"17","author":"Srivastava","year":"2025","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41598-018-20325-0","article-title":"Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry","volume":"8","author":"Tavares","year":"2018","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.3129","article-title":"Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab","volume":"22","author":"Scapin","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"B20","doi-asserted-by":"crossref","unstructured":"FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy\n          \n          \n            \n              Larkins\n              E\n            \n            \n              Blumenthal\n              GM\n            \n            \n              Yuan\n              W\n            \n            \n              He\n              K\n            \n            \n              Sridhara\n              R\n            \n            \n              Subramaniam\n              S\n            \n          \n          10.1634\/theoncologist.2016-0496\n          28533473\n          Oncologist. \n          22\n          2017","DOI":"10.1634\/theoncologist.2016-0496"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00559-9","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial","volume":"23","author":"Long","year":"2022","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet (lond Engl)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-24-27","article-title":"Pembrolizumab in patients with advanced miscellaneous rare cancers: results from a phase 2 basket trial","volume":"8","author":"Nardo","year":"2025","journal-title":"J Immunother Precis Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jclinepi.2021.08.022","article-title":"Cochrane\u2019s risk of bias tool for non-randomized studies (ROBINS-I) is frequently misapplied: A methodological systematic review","volume":"140","author":"Igelstr\u00f6m","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10742-011-0077-3","article-title":"Meta-analysis of cohen\u2019s kappa","volume":"11","author":"Sun","year":"2011","journal-title":"Health Serv Outcomes Res Method"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11135-018-0802-x","article-title":"Fixed and random effects models: making an informed choice","volume":"53","author":"Bell","year":"2019","journal-title":"Qual Quant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.07.028","article-title":"Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial","volume":"159","author":"Lee","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252665","article-title":"Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer","volume":"16","author":"Walsh","year":"2021","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003122","article-title":"Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates","volume":"9","author":"Liao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.04.011","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study","volume":"186","author":"Gonz\u00e1lez-Mart\u00edn","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2405.12437","article-title":"Considerations for single-arm trials to support accelerated approval of oncology drugs","author":"Lu","year":"2024","journal-title":"arXiv"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00225","article-title":"Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival","volume":"41","author":"Merino","year":"2023","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2147\/OTT.S46301","article-title":"Current status of bevacizumab in advanced ovarian cancer","volume":"22","author":"Rossi","year":"2013","journal-title":"OncoTargets Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN guidelines\u00ae insights: ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer, version 3.2024","volume":"22","author":"Liu","year":"2024","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1526103","article-title":"Efficacy and safety of camrelizumab for the treatment of cervical cancer: a systematic review and meta-analysis","volume":"14","author":"Mi","year":"2024","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: A phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.03.027","article-title":"Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016","volume":"186","author":"Gien","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae413","article-title":"Differential functional change in olfactory bulb and olfactory eloquent areas in parkinson\u2019s disease","volume":"6","author":"Luo","year":"2024","journal-title":"Brain Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.893239","article-title":"Dissociation in neural correlates of hyperactive\/impulsive vs. Inattentive symptoms in attention-deficit\/hyperactivity disorder","volume":"16","author":"Luo","year":"2022","journal-title":". Front Neurosci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2018.08.005","article-title":"Aging and the immune system: an overview","volume":"463","author":"Sadighi Akha","year":"2018","journal-title":"J Immunol Methods"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1454","article-title":"Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer","volume":"9","author":"Sceneay","year":"2019","journal-title":"Cancer Discov"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1405","article-title":"Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80\u2009years or older","volume":"4","author":"Saito","year":"2021","journal-title":"Cancer Rep (hob NJ)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jclinepi.2019.05.033","article-title":"Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies","volume":"114","author":"Ladanie","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5985","article-title":"Use of single-arm trials for US food and drug administration drug approval in oncology, 2002-2021","volume":"9","author":"Agrawal","year":"2023","journal-title":"JAMA Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1136\/spcare-2024-004984","article-title":"Single-arm clinical trials: design, ethics, principles","volume":"15","author":"Wang","year":"2024","journal-title":"BMJ Support Palliat Care"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1662455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:52:01Z","timestamp":1759297921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1662455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2025.1662455"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1662455","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"article-number":"1662455"}}